Puma Biotechnology Soars After Positive Briefing Documents By FDA For Neratinib
May 22, 2017 at 20:21 PM EDT
Puma Biotechnology stock soars 50% on release of positive briefing docs but analysts still warn that approval is no sure thing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.